Lutetium Lu 177 Dotatate (Lutathera) and Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) (CPB 0929, reviewed 2026-07-17)
Aetna's policy covers lutetium Lu 177 dotatate (Lutathera) and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) for commercial medical plans. Lutathera is medically necessary for four doses total for specified somatostatin receptor-positive neuroendocrine tumors, poorly controlled carcinoid syndrome, and pheochromocytoma/paraganglioma when the listed criteria are met, and Pluvicto is medically necessary for up to 6 total doses lifetime for PSMA-positive metastatic castration-resistant prostate cancer when all listed criteria are met. Aetna considers both drugs experimental, investigational, or unproven for all other indications, including Lutathera for medullary thyroid carcinoma and meningioma.